All In Biotech

NDA 215014 · Apellis Pharms

Empaveli

Pegcetacoplan · Subcutaneous · Complement Inhibitor

NovelPriority reviewOrphan

CDER novel approval, May 14, 2021: To treat paroxysmal nocturnal hemoglobinuria

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

May 14, 2021

Approved uses

4

Original approval plus efficacy supplements

Registered trials

30

12 Phase 3, 6 recruiting

FAERS reports

1,188

796 serious, 92 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA EMPAVELI, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae , Neisseria meningitidis , and Haemophilus influenzae type B [see Warnings and Precautions (5.1) ] . Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, unless the risks of delaying therapy with EMPAVELI outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated...

What it is approved for

From the label in effect Aug 21, 2026.

EMPAVELI is a complement inhibitor indicated: for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function. ( 1.2 ) 1.1 Paroxysmal Nocturnal Hemoglobinuria EMPAVELI ® is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). 1.2 C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis EMPAVELI ® is indicated for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function.

Mechanism: Pegcetacoplan binds to complement protein C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation. In PNH, extravascular hemolysis (EVH) is facilitated by C3b opsonization while intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC). Pegcetacoplan acts proximally in the complement cascade controlling both C3b-mediated EVH and terminal complement-mediated IVH. In C3G and primary IC-MPGN, complement dysregulation and overactivation causes deposition of C3 fragments in...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 20, 2026 Supplement 12 · Efficacy OrphanLetterLabel
  • Jul 28, 2025 Supplement 11 · Efficacy · priority review OrphanLabelMedication GuideLetter
  • Feb 8, 2023 Supplement 2 · Efficacy OrphanLabel
  • May 14, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • EMPAVELI · PEGCETACOPLAN 1080MG/20ML (54MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegcetacoplan" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue157
  • off label use142
  • haemoglobin decreased128
  • haemolysis109
  • breakthrough haemolysis96
  • headache75
  • drug ineffective67
  • product dose omission issue62
  • covid-1957
  • diarrhoea57
  • pyrexia56
  • platelet count decreased54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202122
202256
2023110
2024540
2025218
2026242

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Empaveli (PEGcetacoplan)

2024 spending

$28.6M

Beneficiaries

71

704 claims

Per beneficiary

$402,313

$240.76 per unit

View as table
YearSpending
2020$0
2021$4,047,059
2022$16,547,290
2023$25,176,818
2024$28,564,239

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Apellis Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.